Publication | Closed Access

Daclizumab is Associated With Decreased Rejection and No Increased Mortality in Cardiac Transplant Patients Receiving MMF, Cyclosporine, and Corticosteroids

TransplantationCardiovascular DiseaseImmunosuppressive TherapyTransplantation MedicineImmunologyDecreased RejectionPharmacotherapyGraft RejectionImmunotherapyMedicineCell TransplantationCardiologyHeart Transplantation